These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20722595)

  • 1. Carbapenems in the treatment of intra-abdominal infection. Report from the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, 10-13 April 2010.
    Lumb J
    Future Microbiol; 2010 Aug; 5(8):1165-6. PubMed ID: 20722595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving outcomes in the management of Gram-negative bacterial infections in the face of growing antimicrobial resistance.
    Mayor S
    Future Microbiol; 2016 Oct; 11():1223-1226. PubMed ID: 27680185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
    Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple colonization with carbapenem-resistant Gram-negative bacteria acquired in India and transferred to Switzerland.
    Mueller L; Ottiger C; Demord A; Poirel L; Nordmann P
    Infection; 2019 Aug; 47(4):669-671. PubMed ID: 30972715
    [No Abstract]   [Full Text] [Related]  

  • 9. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tebipenem, the first oral carbapenem antibiotic.
    Jain A; Utley L; Parr TR; Zabawa T; Pucci MJ
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):513-522. PubMed ID: 30014729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.
    Papst L; Beović B; Pulcini C; Durante-Mangoni E; Rodríguez-Baño J; Kaye KS; Daikos GL; Raka L; Paul M;
    Clin Microbiol Infect; 2018 Oct; 24(10):1070-1076. PubMed ID: 29410094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).
    Biedenbach DJ; Bouchillon SK; Hoban DJ; Hackel M; Phuong DM; Nga TT; Phuong NT; Phuong TT; Badal RE
    Diagn Microbiol Infect Dis; 2014 Aug; 79(4):463-7. PubMed ID: 24923210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.
    Mazzariol A; Bazaj A; Cornaglia G
    J Chemother; 2017 Dec; 29(sup1):2-9. PubMed ID: 29271736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of carbapenems in initial therapy for serious Gram-negative infections.
    Rahal JJ
    Crit Care; 2008; 12 Suppl 4(Suppl 4):S5. PubMed ID: 18495062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.